$2975 | SAVE $525 | Single User
$5950 | SAVE $1,050 | Site License
$8925 | SAVE $1,575 | Enterprise License

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Pipeline Review, H2 2016
[Published by Global Markets Direct]

Published by Global Markets Direct: 26 Oct 2016 | 20632 | In Stock
Related Topics: Protein

Introduction

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Pipeline Review, H2 2016’, provides in depth analysis on Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted pipeline therapeutics.

The report provides comprehensive information on the Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2)

- The report reviews Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics and enlists all their major and minor projects

- The report assesses Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Pipeline Review, H2 2016 [Published by Global Markets Direct]

  • Table of Contents

    Table of Contents 2

    List of Tables 5

    List of Figures 5

    Introduction 6

    Global Markets Direct Report Coverage 6

    Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) Overview 7

    Therapeutics Development 8

    Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Products under Development by Stage of Development 8

    Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Products under Development by Therapy Area 9

    Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Products under Development by Indication 10

    Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Pipeline Products Glance 11

    Late Stage Products 11

    Early Stage Products 12

    Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Products under Development by Companies 13

    Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Therapeutics Assessment 15

    Assessment by Monotherapy/Combination Products 15

    Assessment by Mechanism of Action 16

    Assessment by Route of Administration 17

    Assessment by Molecule Type 18

    Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Companies Involved in Therapeutics Development 19

    Allergan Plc 19

    Brickell Biotech, Inc. 20

    Ligand Pharmaceuticals, Inc. 21

    Merck & Co., Inc. 22

    Novartis AG 23

    Oxagen Limited 24

    Panmira Pharmaceuticals, LLC. 25

    Pulmagen Therapeutics LLP 26

    Taisho Pharmaceutical Holdings Co., Ltd. 27

    Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Drug Profiles 28

    ADC-3680 - Drug Profile 28

    Product Description 28

    Mechanism Of Action 28

    R&D Progress 28

    ADC-7405 - Drug Profile 30

    Product Description 30

    Mechanism Of Action 30

    R&D Progress 30

    ADC-9971 - Drug Profile 31

    Product Description 31

    Mechanism Of Action 31

    R&D Progress 31

    AM-211 - Drug Profile 32

    Product Description 32

    Mechanism Of Action 32

    R&D Progress 32

    AM-461 - Drug Profile 33

    Product Description 33

    Mechanism Of Action 33

    R&D Progress 33

    BBI-5000 - Drug Profile 34

    Product Description 34

    Mechanism Of Action 34

    R&D Progress 34

    fevipiprant - Drug Profile 35

    Product Description 35

    Mechanism Of Action 35

    R&D Progress 35

    MK-1029 - Drug Profile 37

    Product Description 37

    Mechanism Of Action 37

    R&D Progress 37

    OC-2417 - Drug Profile 38

    Product Description 38

    Mechanism Of Action 38

    R&D Progress 38

    setipiprant - Drug Profile 39

    Product Description 39

    Mechanism Of Action 39

    R&D Progress 39

    Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases - Drug Profile 41

    Product Description 41

    Mechanism Of Action 41

    R&D Progress 41

    TASP-0376377 - Drug Profile 42

    Product Description 42

    Mechanism Of Action 42

    R&D Progress 42

    Timapiprant - Drug Profile 43

    Product Description 43

    Mechanism Of Action 43

    R&D Progress 43

    Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Dormant Projects 46

    Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Discontinued Products 49

    Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Featured News & Press Releases 50

    Sep 28, 2016: Eleventa Announce Completion of Patient Enrollment in Phase 3 Clinical Trial of CRTH2 Antagonist Timapiprant for the Treatment of Allergic Asthma 50

    Aug 05, 2016: Asthma pill could reduce symptoms in severe sufferers 50

    Sep 22, 2015: KYTHERA Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia, or Male Pattern Hair Loss 52

    Jun 16, 2015: Atopix Therapeutics Secures Funding to Broaden Development of CRTH2 Antagonists for TH2-Mediated Disease 53

    Aug 01, 2014: Pulmagen’s lead CRTh2 antagonist, ADC3680, completes patient recruitment in Phase II study 53

    Mar 03, 2014: Atopix Therapeutics Announces Positive Phase IIb Results for Once Daily OC459 in Asthma 54

    Nov 19, 2013: Atopix Therapeutics Recruits First Patient in Phase 2 Trial of OC459 for Atopic Dermatitis 54

    May 29, 2013: Atopix Therapeutics Receives Biomedical Catalyst Grant To Pursue Development Of OC459 In Treatment Of Atopic Dermatitis 55

    Jul 15, 2011: Oxagen Announces Publication Of Phase IIa Asthma Trial Data For OC000459 Which Shows Promise As New Oral Treatment For Asthma And Related Disorders 56

    May 23, 2011: Actelion's CRTH2 Antagonist Meets primary Endpoint in Phase II Study in Patients with Seasonal Allergic Rhinitis 56

    May 26, 2010: Amira Announces Second DP2 Antagonist Patent Grant In UK 57

    Dec 09, 2009: Oxagen Announces Completion Of Recruitment In Phase IIb Dose Range-Finding Clinical Trial In New Oral Treatment For Asthma 57

    Dec 09, 2009: Oxagen Completes Recruitment Of Patients For Phase IIb Clinical Trial Of OC000459 For Asthma 58

    Dec 03, 2009: Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data Of AM461 58

    Dec 03, 2009: Amira Pharmaceuticals Announces Phase 1 Clinical Results Of AM461, For The Novel Treatment Of Asthma, Chronic Obstructive Pulmonary Disease (COPD) And Allergic Rhinitis. 59

    Appendix 60

    Methodology 60

    Coverage 60

    Secondary Research 60

    Primary Research 60

    Expert Panel Validation 60

    Contact Us 60

    Disclaimer 61

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

20632 | GMDHC0607TDB

Number of Pages

61

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! DP1 Receptor (Prostaglandin D2 receptor) Antagonists -Pipeline Insights, 2017
DelveInsight’s, “DP1 Receptor (Prostaglandin D2 receptor) Antagonists-Pipeline Insights, 2017”, repo...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Prostacyclin (Prostaglandin I2) Receptor Agonists -Pipeline Insights, 2017
DelveInsight’s, “Prostacyclin (Prostaglandin I2) Receptor Agonists-Pipeline Insights, 2017”, report ...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Prostaglandin Antagonists -Pipeline Insights, 2017
DelveInsight’s, “Prostaglandin Antagonists-Pipeline Insights, 2017”, report provides in depth insigh...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Prostaglandin E Receptor 1 (EP1 or Prostaglandin E1 Receptor EP1 Subtype) Agonists -Pipeline Insights, 2017
DelveInsight’s, “Prostaglandin E Receptor 1 (EP1 or Prostaglandin E1 Receptor EP1 Subtype) Agonists-...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Prostaglandin E Receptor 1 (EP1 or Prostaglandin E1 Receptor EP1 Subtype) Antagonists -Pipeline Insights, 2017
DelveInsight’s, “Prostaglandin E Receptor 1 (EP1 or Prostaglandin E1 Receptor EP1 Subtype) Antagonis...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Prostaglandin E Receptor 2 (EP2 or Prostaglandin E2 Receptor EP2 Subtype) Agonists -Pipeline Insights, 2017
DelveInsight’s, “Prostaglandin E Receptor 2 (EP2 or Prostaglandin E2 Receptor EP2 Subtype) Agonists-...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Prostaglandin E2 (PGE2) Receptor Antagonists -Pipeline Insights, 2017
DelveInsight’s, “Prostaglandin E2 (PGE2) Receptor Antagonists-Pipeline Insights, 2017”, report provi...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Prostaglandin F2-Alpha Receptor (PGF receptor or Prostanoid FP Receptor) Antagonists -Pipeline Insights, 2017
DelveInsight’s, “Prostaglandin F2-Alpha Receptor (PGF receptor or Prostanoid FP Receptor) Antagonist...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Prostaglandin F2-Alpha Receptor Agonists -Pipeline Insights, 2017
DelveInsight’s, “Prostaglandin F2-Alpha Receptor Agonists-Pipeline Insights, 2017”, report provides ...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Pipeline Review, H2 2016
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Pipeline Review, H2 2016...
26 Oct 2016 by Global Markets Direct USD $2,975 (normally
USD $3,500)
More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Pipeline Review, H2 2016 [Published by Global Markets Direct] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...